Glaxo files applications in Europe for expanded use of Nucala

• GlaxoSmithKline (GSK -0.4%) has submitted supplement marketing applications to the European Medicines Agency seeking approval to use Nucala (mepolizumab) to treat hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic granulomatosis with polyangiitis (EGPA).
• The IL-5 antagonist is currently approved in Europe as an add-on treatment for patients with severe eosinophilic asthma.
• The product accounted for almost 3% of the company's Q3 revenues.
• https://seekingalpha.com/news/3628355-glaxo-files-applications-in-europe-for-expanded-use-of-nucala